Konferenzen  >  Medizin & Gesundheitswesen  >  Translationale Medizin, Klinische Studien

ESMO - European Society for Medical Oncology

The ESMO Asia Congress 2023 will welcome you in Singapore from 1 to 3 December, to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level, and for the Asia-Pacific region. The outstanding scientific programme will cover the latest advances on the most prevalent cancer types in the region, offering high quality multidisciplinary educational sessions and special sessions in collaboration with illustrious international and Asia-Pacific oncology associations.

As usual, there will be a special focus on the Pan-Asian Guidelines Adaptation (PAGA) Lectures, conceived to share best practice standards of care for cancer patients and providing a framework for the structured interaction of key opinion leaders in oncology from Asia and Europe.

We hope you will be part of that journey by attending ESMO Asia 2023, where we will unite the Asian and global oncology community and share unforgettable moments!

Email: asiacongress@esmo.org

Breast cancer, CNS, Developmental and precision medicine, gastrointestinal tumours, genitourinary tumours, gynaecological malignancies, head and neck cancer, investigational immunotherapy, melanoma, public policy, sarcoma, rare tumours, thoracic cancer, oncology

Onkologie,    Pharmakogenomik, Personalisierte Medizin

Bioevents Ltd

It is our pleasure to invite you to participate in the upcoming 5th European Congress on Clinical Trials in Pain (SOPATE2023) which will take place 7-8 December 2023 in Brussels, Belgium.

Chronic pain is a complex biopsychosocial phenomenon with a variety of heterogeneous clinical manifestations, pain phenotypes and co-morbidities. The management of chronic pain is still a challenge and we desperately need novel therapeutic approaches. In recent years many clinical trials addressing chronic pain failed to meet the trial endpoint despite encouraging data from preclinical research. One reason for this is that clinical trials have deficits in defining the correct inclusion/exclusion criteria, the correct endpoints and measures for clinically meaningful improvement. Furthermore, the concept that a specific treatment is only beneficial for a subgroup of patients and not for the entire group comes more and more into the focus of clinical trial design.

This Congress will bring together researchers, clinicians, industry professionals and other related experts to look at ways of improving the situation by developing better ideas and practices in clinical trials on pain and address medical devices and other interventions in the treatment and management of chronic pain.

The SOPATE2023 program will include a wealth of knowledge from our world renowned panel of experts.

Ilana Berkowitz;     Tel.: [0044-203-051-4032 ext 525];     Email: ilana@bioevents-congress.com

acute pain, chronic pain, back pain, neropathic pain, pain in osteoarthritis, pain in rheumatoid arthritis, headache, migraine, fibromyalgio, phase 2 studies, phase 3 studies, phase 4 studies, prediction of treatment response, patient reported outcomes, alternate trial design approaches, alternative outcome measures

Fortbildung für Gesundheitsfachberufe (CME),    Anästhesie und Schmerztherapie

The European Association for Cancer Research (EACR)

Discover the hidden world of cancer signaling circuits with leading experts at this EACR Virtual Conference! This conference will focus on basic mechanisms controlling cancer cell signaling circuits at the epigenome, transcriptome, proteome, and phosphoproteome levels. The talks will also focus on therapeutic targeting of cancer cell signaling circuits by conventional and emerging pharmacological strategies, and the mechanistic aspects of post translational and transcriptional regulation of cancer cell signaling, as well as large OMICS-based global understanding of cancer cell signaling circuits.

The target audience for this conference is: scientists in academia and industry who are interested in the most recent developments in non-genetic signaling mechanisms and their roles in cancer progression and therapy resistance.

Conference Officer: Chris Iliffe;     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer signaling circuits, cancer tissue phenotypes, targeted cancer therapies, cancer therapy resistance, non-genetic signaling rewiring, post-translational protein regulation, transcriptional gene regulation, cancer progression, epigenomics, transcriptomics, proteomics, phosphoproteomics, kinases and phosphatases, cancer cell plasticity, cancer research, oncology

Onkologie,    Genomforschung und Bioinformatik

ITOC is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the Wolfgang Wilmanns Stiftung (WWS), the German Cancer Consortium (DKTK), the Chinese American Hematologist and Oncologist Network (

The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.

Event Secretariat;     Tel.: [+431405138318];     Email: itoc@wma.co.at

Basic Tumor Immunology, New Targets and New Leads, Exploiting B Cells and Other Cell Types, Microbiome, Adjuvant vs Neoadjuvant IO Treatment, Combination Therapies, Immuno-Monitoring, Reaching New Grounds in Cellular Therapies, Cell therapies in Hematologic Oncology, Cell Therapies in Solid Oncology

Onkologie,    Immunologie und Allergie

European Society for Medical Oncology (ESMO)

Brought to you by the European Society for Medical Oncology (ESMO), the congress will be the place to present very impactful new data in GI oncology. The scientific sessions will be complemented with high quality educational sessions and excellent networking opportunities.

In recent years we have seen remarkable progress in the treatment options available for patients with GI cancers and ESMO is committed to ensuring that there is a clear roadmap to help facilitate the implementation of new practice changing discoveries in the clinic for the benefit of all patients with GI cancers and whose wellbeing is our primary concern. The ESMO Gastrointestinal Cancers Congress will provide global visibility for original clinical and translational research.

Tel.: [+41 (0)91 973 19 62];     Email: gicongress@esmo.org

Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Pancreatic Cancer, Biliary Tract Cancer, Neuroendocrine Tumors, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Gastrointestinal Cancers

Onkologie,    Gastroenterologie